In the rush to market, be aware of these critical missteps that can occur during the early development phases, in order to avoid major challenges later during commercial API scale-up.
Over the life of a drug, changes in raw materials are almost inevitable. But even a small modification can throw your drug out of compliance. Using case studies, the author explains how to safeguard drug integrity when raw materials change.
With few potential blockbuster drugs in the pharma pipeline right now, drug companies are increasingly looking at other options to meet the needs of patients and increase revenue in the oral solid dosage arena.
Sterile suspensions are particularly difficult to manufacture. This technical article covers factors for success, including particle size, vehicle formulation, and considerations for high-shear mixing.
Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies.
When developing a parenteral product, pharmaceutical scientists are faced with a variety of choices – choices that can be conflicting or present differing advantages. With careful planning and strategic foresight, these advantages can be leveraged to great effect during the development program. Read the whitepaper to learn more.
OptiForm® Solution Suite is a comprehensive offering which incorporates everything you need to progress your candidate from late-stage discovery to phase I.
A platform that combines drug development expertise and biomanufacturing and integrated services to offer advantages to ADC developers.
This webinar explores use cases showing how machine learning and analytics can help overcome the challenges facing the biopharma industry through more confident data-driven decisions.
Striving to bring the way we acquire, share and gain insights from scientific data, through a community and the framework for standardization and linked data.
With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins.
The complex structure of Biologics, the nature of the interactions with their partners, require accurate modelling method to predict their physicochemical properties.
Committed to perfecting cell culture at every scale - The Thermo Scientific Nunc Cell Factory System Difference.
Piramal Pharma Solutions is the contract development and manufacturing (CDMO) arm of Piramal Enterprises Ltd., having a vast network of development and manufacturing facilities located in North America, Europe and Asia.
Custom solutions tailored to suit your bioproduction needs.